T. Rowe Price Investment Management
MRNA icon

T. Rowe Price Investment Management’s Moderna MRNA Stock Holding History

T. Rowe Price Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,022
Closed -$31K – 832
2025
Q4 		$31K Buy
1,022
+129
+14% +$3.5K ﹤0.01% 677
2025
Q3 		$24K Buy
893
+212
+31% +$5.91K ﹤0.01% 675
2025
Q2 		$19K Buy
+681
New +$17.9K ﹤0.01% 674

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Investment Management's MRNA Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Moderna (MRNA) in Q1 2026, closing a stake of 1,022 shares — an estimated $31K sold.

T. Rowe Price Investment Management first reported a position in MRNA in Q2 2025 and held it in 3 quarters. The position peaked at $31K in Q4 2025. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,022 Moderna shares in Q1 2026, an estimated $31K.
  • T. Rowe Price Investment Management first reported a position in Moderna in Q2 2025 and held it in 3 quarters.
  • T. Rowe Price Investment Management's Moderna position peaked at $31K in Q4 2025.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.